EPZ-6438

CHF 55.00
In stock
AG-CR1-3743-M0055 mgCHF 55.00
AG-CR1-3743-M01010 mgCHF 80.00
AG-CR1-3743-M02525 mgCHF 115.00
AG-CR1-3743-M100100 mgCHF 230.00
More Information
Product Details
Synonyms Tazemetostat; E7438
Product Type Chemical
Properties
Formula

C34H44N4O4

MW 572.7
CAS 1403254-99-8
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (25mg/ml).
Identity Determined by 1H-NMR.
InChi Key NSQSAUGJQHDYNO-UHFFFAOYSA-N
Smiles CC(N1)=CC(C)=C(CNC(C2=CC(C3=CC=C(CN4CCOCC4)C=C3)=CC(N(CC)C5CCOCC5)=C2C)=O)C1=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • EPZ-6438 is a potent orally bioavailable, selective inhibitor of the lysine methyltransferase EZH2 (Ki = 2.5nM), the enzymatic subunit of polycomb repressive complex 2 (PRC2) catalyzing the methylation of lysine 27 of histone H3 (H3K27). EPZ-6438 competitively binds to the S-adenosylmethionine (SAM) binding site of EZH2 and non-competitively to the binding sites of peptide or nucleosome substrate. It shows also in vitro potency for EZH2 mutations (Y641F, C, H, N, S and A677G). PRC2 is the only protein methyltransferase that can methylate H3K27 and H3K27 is the only significant substrate for PRC2. Aberrant trimethylation of H3K27 is oncogenic in a broad spectrum of human cancers such as B cell NHL.
  • EPZ-6438 blocks histone H3 lysine 27 trimethylation in both wild-type and mutant lymphoma cells (IC50 range from 2-90nM). EPZ-6438 selectively inhibits EZH2 with selectivity 35-fold greater than EZH1 and >4,500-fold to other histone methyl transferases, including G9a, GLP, SETD7, SMYD2, SMYD3, MMSET, WHSC1L1, PRMTs, DOT1L.
  • EPZ-6438 has potent anticancer properties. It is potent in cellular antiproliferation assays (IC50 ~100nM), inducing apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumor (MRT) cells promoting their regression in xenograft-bearing mice.
  • EPZ-6438 has been shown to have anti-neuroinflammatory properties by modulating interferon regulatory factor (IRF) 1, IRF8 and signal transducer and activator of transcription (STAT) 1 levels.
  • EPZ-6438 inhibitors induced anti-inflammatory effects (reducing expression levels of IL-6, IL-1β, IFN-γ, TGFβ and CTGF for inflammation) in liver tissues and may represent a promising target in the treatment of non-alcoholic steatohepatitis (NASH), a progressive disease of NAFLD which leads to fibrosis, cirrhosis and hepatocellular carcinoma.
  • Latent HIV reservoirs are resting immune cells that are infected with HIV but not actively producing HIV. Latent HIV reservoirs are established during the earliest stage of HIV infection. Although antiretroviral therapy (ART) can reduce the level of HIV in the blood to an undetectable level, latent reservoirs of HIV continue to survive. Inhibition of EZH2 by EPZ-6438, in a model of HIV latency on immune cells isolated from HIV-1-infected patients receiving highly active antiretroviral therapy, induced the reactivation of latent proviruses and might be an approach of reversing latency in HIV.
Product References
  1. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2: S.K. Knutson, et al.; PNAS 110, 7922 (2013)
  2. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma: S.K. Knutson, et al.; Mol. Cancer Ther. 13, 842 (2014)
  3. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas: S.K. Knutson, et al.; PLoS One 9, e111840 (2014)
  4. Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method: T.V. Riera, et al.; Methods Mol. Biol. 1439, 33 (2016)
  5. Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency: K. Nguyen, et al.; mBio 8, e00133 (2017)
  6. Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation: S. Arifuzzaman, et al.; Biochem. Pharmacol. 137, 61 (2017)
  7. Enhancer of zeste homolog 2 (EZH2) inhibitors: N. Gulati, et al.; Leuk. Lymphoma 59, 1574 (2018) (Review)
  8. The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice: S. Lee, et al.; Biology 9, E93 (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.